Search

Your search keyword '"Maria Cappello"' showing total 234 results

Search Constraints

Start Over You searched for: Author "Maria Cappello" Remove constraint Author: "Maria Cappello"
234 results on '"Maria Cappello"'

Search Results

1. SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves

2. A Narrative Review on Eating Disorders and Disordered Eating in Inflammatory Bowel Diseases: Need for Increased Awareness

3. Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data

4. Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases

5. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

6. Inflammation and Aortic Pulse Wave Velocity: A Multicenter Longitudinal Study in Patients With Inflammatory Bowel Disease

9. 4.6 INFLAMMATION AND AORTIC STIFFNESS. A MULTICENTRE LONGITUDINAL STUDY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

10. P191 AORTIC STIFFNESS AND INFLAMMATION IN INFLAMMATORY BOWEL DISEASES: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS

11. Inflammation and Aortic Stiffness: An Individual Participant Data Meta‐Analysis in Patients With Inflammatory Bowel Disease

17. Il contrasto all’odio e alla disinformazione in rete. Prime evidenze dalle campagne del progetto COMMIT

18. Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease

19. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19

20. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology

21. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease

22. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches

23. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)

24. Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study

25. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology

26. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey

27. Media Literacy in <scp>I</scp> taly

28. Critical Theory Applied to Media Literacy

29. Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study

30. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

31. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

32. OC.09.4 PREVALENCE OF NAFLD (NON ALCOHOLIC FATTY LIVER DISEASE) IN INFLAMMATORY BOWEL DISEASE: THE ROLE OF METABOLIC FACTORS, INTESTINAL INFLAMMATION AND GENETIC PHENOTYPE

33. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

34. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy

35. Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

36. A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease

37. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis

38. The ocular manifestations in IBD screening (OMIS) questionnaire: pilot study on detection of ocular involvement in inflammatory bowel diseases

39. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases

40. P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501

41. The Course of COVID-19 in Inflammatory Bowel Disease: Protective Role of TNF Antagonists

42. PC.01.3 SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

43. AF.29 INADEQUATE DIETARY INTAKE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A CROSS-SECTIONAL ANALYSIS IN A HOMOGENEOUS COHORT FROM SOUTHERN ITALY

45. AF.53 THE LEGACY OF COVID-19 PANDEMICS: REMOTE MONITORING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AS AN EFFECTIVE MANAGEMENT STRATEGY

48. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study

50. PC.01.2 A PROPENSITY SCORE WEIGHTED COMPARISON OF VEDOLIZUMAB AND ADALIMUMAB IN CROHN'S DISEASE: REAL-LIFE DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Catalog

Books, media, physical & digital resources